NVCR
What one share of NovoCure Limited holds
Surgical and Medical Instruments and Apparatus
We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device.
NovoCure Limited’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $6.16 |
|---|---|
| Profit | −$1.31 |
| Capex (buildings and equipment) | $0.20 |
| Free cash flow | −$0.22 |
| Cash and investments | $0.80 |
| Debt | $1.68 |
| Book value | $2.90 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | $0.90 | −$6.73 | $0.19 | −$4.78 | — | $14.94 |
| 2014 | $1.24 | −$6.46 | $0.07 | −$6.01 | — | $7.29 |
| 2015 | $1.09 | −$3.67 | $0.15 | −$3.44 | — | — |
| 2016 | $0.97 | −$1.54 | $0.07 | −$1.32 | — | $1.63 |
| 2017 | $2.00 | −$0.70 | $0.08 | −$0.46 | — | $1.27 |
| 2018 | $2.70 | −$0.69 | $0.07 | −$0.09 | — | $1.20 |
| 2019 | $3.61 | −$0.07 | $0.11 | $0.17 | — | $2.19 |
| 2020 | $4.54 | $0.18 | $0.14 | $0.77 | — | $4.66 |
| 2021 | $5.17 | −$0.56 | $0.23 | $0.57 | — | $3.95 |
| 2022 | $5.14 | −$0.88 | $0.20 | $0.09 | — | $4.20 |
| 2023 | $4.79 | −$1.95 | $0.25 | −$0.94 | — | $3.39 |
| 2024 | $5.61 | −$1.56 | $0.40 | −$0.64 | — | $3.32 |
| 2025 | $5.88 | −$1.22 | $0.24 | −$0.68 | — | $3.03 |